RXMD Well that's why they pride themselves for not being the typical pharmacy. Their MTM revenue grew 50% so they have always been ahead of the curve as far as diversifying.
Now, in terms of flat line scripts that's not necessarily an abnormal thing.
I do agree that a second location is what's next for them.
So that's a second location and M&A which would be unreal in terms of catalysts.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.